Amgen and Belgium-based UCB said a two-year, Phase 3 clinical trial shows its jointly developed drug Evenity may prevent bone fractures in women suffering from osteoporosis
Evenity, an injectable drug aimed at stabilizing bones and hastening their formation, stalled spinal and other fractures among post-menopausal women participating in the study, a release from the two companies said.
The study paired Evenity with another compound, alendronate, and found that by the end of two years of treatment, spinal fractures were 50 percent less likely to occur. However, the data also showed a possible link between Evinity and heart disease.
Dr. Sean Harper, Amgen’s executive vice president of research and development, urged caution in light of the potential cardiovascular impact.
"Together with UCB, we will engage with global regulators and medical experts in the field to conduct a thorough evaluation of these data," Harper said in the release.